OncoSec Medical Inc (ONCSQ)

[lasers]

Without a doubt MRK would be considered the #1 candidate to partner with $ONCS for the planned Phase2B Combo. MRK's expected FT approval 2014/2015 for its anti-PD-1/PD-L1 therapy would then lead to Std of Care FDA approved therapy. FDA approval of $ONCS Phase2B Combo in conjunction with MRK would then mean Commercialization for $ONCS Melanoma Combo therapy.